Axsome Therapeutics Inc (AXSM) — Cash Flow-to-Debt Ratio
Axsome Therapeutics Inc (AXSM) has a Cash Flow-to-Debt Ratio of -0.03x as of March 2026, meaning its operating cash flow of $-20.70 Million could theoretically repay 0% of its total liabilities ($659.02 Million) in one year. Check total reinvestment intensity of Axsome Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Axsome Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Axsome Therapeutics Inc across 13 annual periods. Also explore Axsome Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Axsome Therapeutics Inc (2013–2025)
Year-by-year debt coverage analysis for Axsome Therapeutics Inc. For market capitalisation and broader financial context, see AXSM company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.16x | $-93.41 Million | $601.51 Million | ▲ +38.1% |
| 2024 | -0.25x | $-128.41 Million | $511.48 Million | ▲ +31.3% |
| 2023 | -0.37x | $-145.08 Million | $397.26 Million | ▲ +30.4% |
| 2022 | -0.53x | $-116.51 Million | $221.92 Million | ▲ +65.0% |
| 2021 | -1.50x | $-108.23 Million | $72.15 Million | ▼ -38.3% |
| 2020 | -1.08x | $-78.46 Million | $72.34 Million | ▲ +2.2% |
| 2019 | -1.11x | $-46.38 Million | $41.83 Million | ▲ +46.7% |
| 2018 | -2.08x | $-30.05 Million | $14.44 Million | ▼ -48.1% |
| 2017 | -1.41x | $-26.47 Million | $18.84 Million | ▼ -9.9% |
| 2016 | -1.28x | $-21.28 Million | $16.64 Million | ▲ +54.8% |
| 2015 | -2.83x | $-7.44 Million | $2.63 Million | ▼ -268.3% |
| 2014 | -0.77x | $-4.60 Million | $5.99 Million | ▼ -94.1% |
| 2013 | -0.40x | $-1.63 Million | $4.13 Million | — |